
    
      The study will be conducted in accordance with legal and regulatory requirements with
      scientific purpose, value and rigor following generally accepted research practices described
      in Guidelines for Good Pharmacoepidemiology Practices (GPP), Good Epidemiological Practice
      (GEP), Good Practices for Outcomes Research, International Ethical Guidelines for
      Epidemiological Research, European Medicines Agency (EMA) European Network of Centres for
      Pharmacoepidemiology and Pharmacovigilance (ENCePP) Guide on Methodological Standards in
      Pharmacoepidemiology, and FDA Guidance for Industry. Data sources will be validated and will
      consist of the hospital medical records and monitoring will be organized on a regular basis.
      Data sources will be validated. The source data will consist of medical records, physician
      questionnaires, and patient questionnaires. Data for the study will be entered into an
      electronic data capture system. Questionnaires will be completed on electronic tablets. The
      study is a one year enrollment period with a two year follow-up period. The study plans to
      enroll patients throughout Canada and Europe.
    
  